The phase IIa of CBL-514 injection was completed

CBL-514 obtains phase IIa CSR primary and secondary endpoints both are statistically significant with excellent safety and tolerance. The results demonstrated that CBL-514 was able to meet both primary and secondary endpoints, which were statistically significant. The majority of the adverse events was mild with no serious adverse events, systemic risks or sequelaes reported.